CO2023010940A2 - Compuestos moduladores de gcn2 y usos de los mismos - Google Patents
Compuestos moduladores de gcn2 y usos de los mismosInfo
- Publication number
- CO2023010940A2 CO2023010940A2 CONC2023/0010940A CO2023010940A CO2023010940A2 CO 2023010940 A2 CO2023010940 A2 CO 2023010940A2 CO 2023010940 A CO2023010940 A CO 2023010940A CO 2023010940 A2 CO2023010940 A2 CO 2023010940A2
- Authority
- CO
- Colombia
- Prior art keywords
- gcn2
- modulating compounds
- modulating
- compounds
- diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 101150033008 EIF2AK4 gene Proteins 0.000 title 1
- 101000926525 Homo sapiens eIF-2-alpha kinase GCN2 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 102100034175 eIF-2-alpha kinase GCN2 Human genes 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Holo Graphy (AREA)
- Liquid Crystal Substances (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163140314P | 2021-01-22 | 2021-01-22 | |
| PCT/US2022/013383 WO2022159746A1 (en) | 2021-01-22 | 2022-01-21 | Gcn2 modulating compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023010940A2 true CO2023010940A2 (es) | 2023-12-11 |
Family
ID=80446635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0010940A CO2023010940A2 (es) | 2021-01-22 | 2023-08-22 | Compuestos moduladores de gcn2 y usos de los mismos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240083897A1 (enExample) |
| EP (1) | EP4281182A1 (enExample) |
| JP (1) | JP2024504364A (enExample) |
| KR (1) | KR20240021143A (enExample) |
| CN (1) | CN117203206A (enExample) |
| AU (1) | AU2022210760A1 (enExample) |
| BR (1) | BR112023014723A2 (enExample) |
| CA (1) | CA3209124A1 (enExample) |
| CO (1) | CO2023010940A2 (enExample) |
| CR (1) | CR20230408A (enExample) |
| IL (1) | IL304611A (enExample) |
| MX (1) | MX2023008589A (enExample) |
| PE (1) | PE20240691A1 (enExample) |
| WO (1) | WO2022159746A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202008749D0 (en) | 2020-06-09 | 2020-07-22 | Ip2Ipo Innovations Ltd | Novel compounds |
| WO2023230567A1 (en) * | 2022-05-25 | 2023-11-30 | Hibercell, Inc. | Gcn2 modulator for treating cancer |
| WO2024077092A1 (en) * | 2022-10-04 | 2024-04-11 | Hibercell, Inc. | Gcn2 inhibitor for treating metastases |
| IL322199A (en) * | 2023-01-20 | 2025-09-01 | Hibercell Inc | Crystalline forms of 6-(3-((5-chloro-2-methoxypyridine)-3-sulfonamido)-6,2-difluorophenyl)-N-methylimidazo[1, 5-A]pyrazine-1-carboxamide and methods of use are |
| WO2025122985A1 (en) * | 2023-12-08 | 2025-06-12 | Hibercell, Inc. | Methods of treating acute myeloid leukemia using combinations of gcn2 modulators, venetoclax, and azacitidine |
| WO2025137710A1 (en) * | 2023-12-22 | 2025-06-26 | Hibercell, Inc. | Methods of treating cancer using combinations of gcn2 modulators and belzutifan |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004279427B2 (en) * | 2003-10-08 | 2008-07-03 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| ES2422263T3 (es) * | 2008-12-19 | 2013-09-10 | Nerviano Medical Sciences Srl | Pirazoles bicíclicos como inhibidores de la proteinquinasa |
| HRP20241768T1 (hr) * | 2016-08-10 | 2025-02-28 | Takeda Pharmaceutical Company Limited | Heterociklički spoj |
| JP7229257B2 (ja) * | 2018-01-29 | 2023-02-28 | メルク パテント ゲーエムベーハー | Ｇｃｎ２阻害剤およびその使用 |
| US20220388964A1 (en) * | 2019-04-12 | 2022-12-08 | Hibercell, Inc. | (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions |
| JP2023514328A (ja) * | 2020-02-17 | 2023-04-05 | アレスタ・セラピューティクス・ベスローテン・フェンノートシャップ | Ｇｃｎ２モジュレーター化合物 |
-
2022
- 2022-01-21 BR BR112023014723A patent/BR112023014723A2/pt unknown
- 2022-01-21 KR KR1020237028260A patent/KR20240021143A/ko active Pending
- 2022-01-21 CA CA3209124A patent/CA3209124A1/en active Pending
- 2022-01-21 PE PE2023002158A patent/PE20240691A1/es unknown
- 2022-01-21 EP EP22704111.8A patent/EP4281182A1/en active Pending
- 2022-01-21 US US18/262,493 patent/US20240083897A1/en active Pending
- 2022-01-21 WO PCT/US2022/013383 patent/WO2022159746A1/en not_active Ceased
- 2022-01-21 MX MX2023008589A patent/MX2023008589A/es unknown
- 2022-01-21 JP JP2023544292A patent/JP2024504364A/ja active Pending
- 2022-01-21 CR CR20230408A patent/CR20230408A/es unknown
- 2022-01-21 AU AU2022210760A patent/AU2022210760A1/en active Pending
- 2022-01-21 CN CN202280022926.3A patent/CN117203206A/zh active Pending
-
2023
- 2023-07-20 IL IL304611A patent/IL304611A/en unknown
- 2023-08-22 CO CONC2023/0010940A patent/CO2023010940A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024504364A (ja) | 2024-01-31 |
| KR20240021143A (ko) | 2024-02-16 |
| CA3209124A1 (en) | 2022-07-28 |
| CN117203206A (zh) | 2023-12-08 |
| BR112023014723A2 (pt) | 2023-10-03 |
| US20240083897A1 (en) | 2024-03-14 |
| CR20230408A (es) | 2024-05-07 |
| EP4281182A1 (en) | 2023-11-29 |
| IL304611A (en) | 2023-09-01 |
| WO2022159746A1 (en) | 2022-07-28 |
| AU2022210760A1 (en) | 2023-09-07 |
| MX2023008589A (es) | 2023-08-09 |
| PE20240691A1 (es) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023010940A2 (es) | Compuestos moduladores de gcn2 y usos de los mismos | |
| ECSP21086429A (es) | Moduladores de la vía integrada del estrés | |
| CO2021006098A2 (es) | Moduladores de profármacos de la vía de estrés integrada | |
| CO2024000588A2 (es) | Composiciones y métodos para la inhibición de ras | |
| BR112021021754A2 (pt) | Cicloalquilas substituídas como moduladoras da via de estresse integrada | |
| CL2020002573A1 (es) | Inhibidores atf6 y sus usos. | |
| MX2020004538A (es) | Moduladores de la vía de estrés integrada. | |
| MX2020004555A (es) | Moduladores de la vía de estrés integrada. | |
| MX2020004551A (es) | Moduladores de la vía de estrés integrada. | |
| MX2020004557A (es) | Moduladores de la vía de estrés integrada. | |
| CO2026004964A2 (es) | Moduladores de kras | |
| MX2020004534A (es) | Moduladores de la vía integrada del estrés. | |
| UY38377A (es) | Piridazinonas y sus métodos de uso | |
| MX2022010693A (es) | Compuestos, composiciones y metodos para inhibidores de la proteina quinasa que interactua con el receptor i para el tratamiento de enfermedades. | |
| CL2024001566A1 (es) | Moduladores de la vía integrada del estrés | |
| MX2022002446A (es) | Compuestos de pirrolopirimidina inhibidores de perk. | |
| MX2022000646A (es) | Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms). | |
| CL2024000340A1 (es) | Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades | |
| CL2025000272A1 (es) | Derivados de arilo tricíclico y composiciones y métodos de los mismos | |
| CL2024001748A1 (es) | Usos de compuestos biciclicos para el tratamiento de enfermedades. | |
| MX2022000082A (es) | Composiciones terapeuticas y metodos para tratar canceres. | |
| MX2025014319A (es) | Heteroarilamidas biciclicas con actividad moduladora de gpr68 | |
| CL2023000234A1 (es) | Moduladores de la vía de estrés integrada | |
| AR126554A1 (es) | Composiciones y métodos para la inhibición de ras |